-
"Innovative drug brother" stormed the more than 70 billion diabetes drug market
Time of Update: 2023-02-01
It is reported that on January 13, the Center for Drug Evaluation (CDE) of the State Medical Products Administration of China announced that Shengdi Pharmaceutical, a subsidiary of Hengrui Pharmaceutical, has submitted new drug marketing applications for repagliptin metformin tablets (I.
-
Zai Lab will have a number of expected milestones this year, with at least 15 products available by 2025
Time of Update: 2023-02-01
Sulbactam-durlobactam: A combination of β-lactam/β-lactamase inhibitor with unique antibacterial activity against Acinetobacter baumannii, including carbapenem-resistant strains, it has been declared for marketing in China in 2022 and is expected to be approved in the first half of 2023 for infections caused by carbapene-resistant strains (CRAB).
-
With the active cooperation between Incyte and domestic and foreign pharmaceutical companies, two new drugs will be launched in China
Time of Update: 2023-02-01
On January 7, the Center for Drug Evaluation (CDE) of China's State Food and Drug Administration announced that Eli Lilly applied for the marketing of baricitinib tablets for a new indication and was
-
The pharmaceutical company expects to double the number of R&D teams by 2023
Time of Update: 2023-01-05
TF Securities recently said in a research report on Bede Pharmaceutical that the company focuses on the business of drug molecular building blocks and scientific reagents, with outstanding variety richness and quality/price advantages, and the penetration rate of downstream new drug R&D customers has gradually increased; Forward-looking strategic layout in the international market, global multi-center layout in the United States, India, Germany and other places, rich customer resources at home and abroad.
-
This pharmaceutical company continues to enrich its product range, and another new API has been approved for marketing!
Time of Update: 2023-01-05
This product is the first approved transfiberobronchoscopic intratumor-injected chemical ablation drug in China, and it is also the first drug indicated to alleviate severe airway obstruction in adult patients with central non-small cell lung cancer.
-
In order to optimize the asset structure, the pharmaceutical company intends to sell some API production plant assets
Time of Update: 2023-01-05
js?cdnversion='+~(-new Date()/36e5)];Recently, the API industry has been dynamic, including Xinhua Pharmaceutical, Xintiandi Pharmaceutical and other pharmaceutical companies have expressed plans to build production bases in order to break through development.
-
Teripulimab submits UK marketing application Junshi Biologics enters Europe and takes the next city
Time of Update: 2023-01-04
js?cdnversion='+~(-new Date()/36e5)]; This is the second marketing application for teripulimab in Europe, and its global commercialization is progressing steadily On November 24, 2022, Beijing time, Junshi Biologics (1877.
-
This pharmaceutical company's second IPO on the science and technology innovation board was accepted!
Time of Update: 2023-01-04
In this IPO of the Science and Technology Innovation Board, Baiduoan plans to raise 760 million yuan for the industrialization and upgrading project of medical catheters, the construction project of R&D center, the construction project of marketing service network and information technology, and the supplementary working capital project.
-
CXO companies have reduced their holdings significantly, but their development is still optimistic in the industry
Time of Update: 2023-01-01
According to the content of the announcement, WuXi AppTec's actual controller and concerted actors will reduce their holdings by a total of no more than 65 million shares within half a year, that is, no more than 2.
-
The medical circle has opened a "slimming tide"! The pharmaceutical company transferred equity in the subsidiary for 180 million yuan
Time of Update: 2023-01-01
This time, on November 15, Harbour Biopharma also announced that it would sell the production plant of its Biomolecule R&D Innovation Center project to WuXi Hyde, a subsidiary of Biologics Biologics, for a transaction price of 146 million yuan.
-
Shanghai Lu Xiangyi set sail to sea, and another batch of centrifuges was exported to Russia!
Time of Update: 2023-01-01
Since joining the WTO, China has maintained friendly trade relations with many countries, and Russia is one of them. It is reported that China's exports to Russia are mainly mechanical and electrical
-
Hengrui Pharmaceutical accelerated the pace of industrial investment, and the long-term investment and output increased by more than 7 times in two years
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];On December 2, Hengrui Pharmaceutical issued an announcement that as of November 30, the company has repurchased about 12 million shares of its own shares, with a transaction price range of 27.
-
This pharmaceutical company abandoned the biomedical business to focus on the development of traditional Chinese medicine
Time of Update: 2023-01-01
Jingjing Pharmaceutical pointed out that during the "14th Five-Year Plan" period, the company planned to put forward a "two-wheel drive" development strategy focusing on the main business of "five golden flowers" traditional Chinese medicine, supplemented by characteristic chemical APIs and chemical preparations, and continuously improving competitiveness.
-
The internationalization of this domestic pharmaceutical company "accelerated", and new drugs submitted marketing applications in Europe!
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];Recently, Hansen Pharmaceutical announced that the European Medicines Agency (EMA) has officially accepted the marketing application of ametinib mesylate tablets submitted by the company's partner EQRx for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-sensitive mutations, and for the treatment of locally advanced or metastatic NSCLC adult patients with EGFR T790M mutation-positive.
-
During the year, the pharmaceutical company has reviewed 8 generic drugs
Time of Update: 2023-01-01
For example, recently, Liaoning Fangda Group Northeast Pharmaceutical announced that it had received the "Drug Supplement Application Approval Notice" for the company's Piracetam tablets approved and issued by the National Medical Products Administration, marking that the product successfully passed the consistency evaluation of the quality and efficacy of generic drugs.
-
In 2023, the pharmaceutical company will actively carry out 10 consistency evaluation projects
Time of Update: 2022-12-29
js?cdnversion='+~(-new Date()/36e5)];It is of great significance to carry out the consistency evaluation of the quality and efficacy of generic drugs, which can enhance the brand value of products and enhance the discourse power of product markets, which has been paid more and more attention by pharmaceutical companies.
-
Xintian Pharmaceutical was surveyed by 17 institutions and strives to account for 50% or more of OTC market sales
Time of Update: 2022-11-26
Xintian Pharmaceutical said that the company's current leading products have entered the "fast lane of development" with a single product sales scale of more than 100 million, based on the company's long-term adherence to the clinical efficacy-oriented modern innovative Chinese medicine pharmaceutical concept and strict product market selection mechanism, since the expansion of OTC market channels in 2018, the out-of-hospital market with clinical efficacy has achieved remarkable results.
-
The pharmaceutical company announced on the same day that 3 new drugs were approved for clinical trials!
Time of Update: 2022-11-25
js?cdnversion='+~(-new Date()/36e5)];At present, a large number of pharmaceutical companies are actively responding to national policies, constantly adapting to the higher requirements brought by industrial changes, and continuing to steadily promote scientific and technological innovation.
-
Another ophthalmic medical company will IPO, and the competition on the track will intensify
Time of Update: 2022-11-04
88 yuan per share, and is expected to land on the Growth Enterprise Market of the Shenzhen Stock Exchange in early November.
88 yuan per share, and is expected to land on the Growth Enterprise Market of the Shenzhen Stock Exchange in early November.
-
Another pharmaceutical company Class 1 new drug welcomes a new breakthrough!
Time of Update: 2022-10-31
js?cdnversion='+~(-new Date()/36e5)]; Recently, East Sunshine Pharmaceutical initiated a Phase III clinical trial to evaluate the efficacy and safety of creftinib besylate tablets in patients with relapsed/refractory acute myeloid leukemia (AML) with FLT3-ITD mutations.
